Achillion Pharmaceuticals (ACHN) Shares are Down -1.83%

Achillion Pharmaceuticals (ACHN) has risen sharply, recording gains of 6.7% in the past 4 weeks. However, the stock has corrected -1.83% in the past 1 week, providing a good buying opportunity on dips. Achillion Pharmaceuticals (ACHN) : During the past 4 weeks, traders have been relatively bearish on Achillion Pharmaceuticals (ACHN), hence the stock is down -0.05% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.43% relative to the S&P 500.

Achillion Pharmaceuticals (NASDAQ:ACHN): The stock opened at $8.76 on Friday but the bulls could not build on the opening and the stock topped out at $8.84 for the day. The stock traded down to $8.56 during the day, due to lack of any buying support eventually closed down at $8.60 with a loss of -1.94% for the day. The stock had closed at $8.77 on the previous day. The total traded volume was 926,612 shares.


The stock has recorded a 20-day Moving Average of 1.61% and the 50-Day Moving Average is 1.32%. Achillion Pharmaceuticals, Inc. has dropped 5.49% during the last 3-month period . Year-to-Date the stock performance stands at -20.3%.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.